BE1023557B1 - Systeme, appareil et procede pour la production de biomolecules - Google Patents
Systeme, appareil et procede pour la production de biomolecules Download PDFInfo
- Publication number
- BE1023557B1 BE1023557B1 BE2015/5060A BE201505060A BE1023557B1 BE 1023557 B1 BE1023557 B1 BE 1023557B1 BE 2015/5060 A BE2015/5060 A BE 2015/5060A BE 201505060 A BE201505060 A BE 201505060A BE 1023557 B1 BE1023557 B1 BE 1023557B1
- Authority
- BE
- Belgium
- Prior art keywords
- bioreactor
- cells
- cell
- culture medium
- downstream unit
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 74
- 239000001963 growth medium Substances 0.000 claims abstract description 66
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
- 238000012258 culturing Methods 0.000 claims abstract description 10
- 239000012530 fluid Substances 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 132
- 238000004113 cell culture Methods 0.000 claims description 44
- 238000000746 purification Methods 0.000 claims description 38
- 238000001914 filtration Methods 0.000 claims description 32
- 239000007789 gas Substances 0.000 claims description 28
- 239000001301 oxygen Substances 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 238000012546 transfer Methods 0.000 claims description 23
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 22
- 230000010261 cell growth Effects 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 210000004748 cultured cell Anatomy 0.000 claims description 12
- 238000001802 infusion Methods 0.000 claims description 10
- 238000000502 dialysis Methods 0.000 claims description 8
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 230000006037 cell lysis Effects 0.000 claims 1
- 239000006228 supernatant Substances 0.000 description 48
- 239000000047 product Substances 0.000 description 44
- 239000002609 medium Substances 0.000 description 31
- 239000000872 buffer Substances 0.000 description 12
- 229920001410 Microfiber Polymers 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 239000003658 microfiber Substances 0.000 description 10
- 238000011026 diafiltration Methods 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000012669 liquid formulation Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 229940036185 synagis Drugs 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008246 gaseous mixture Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000003771 C cell Anatomy 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229960000446 abciximab Drugs 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 229960004669 basiliximab Drugs 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000011035 continuous diafiltration Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007792 gaseous phase Substances 0.000 description 2
- 229960000578 gemtuzumab Drugs 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 229950010203 nimotuzumab Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960000470 omalizumab Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- MWRWFPQBGSZWNV-UHFFFAOYSA-N Dinitrosopentamethylenetetramine Chemical compound C1N2CN(N=O)CN1CN(N=O)C2 MWRWFPQBGSZWNV-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940038444 antibody-based vaccine Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- -1 buffers Chemical class 0.000 description 1
- 229940112112 capex Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000011036 discontinuous diafiltration Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/14—Bioreactors or fermenters specially adapted for specific uses for producing enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/18—Apparatus specially designed for the use of free, immobilized or carrier-bound enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/52—Mobile; Means for transporting the apparatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/10—Perfusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/12—Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Sustainable Development (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Clinical Laboratory Science (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (15)
- REVENDICATIONS1. Procédé automatisé intégré pour la production d'anticorps comprenant : a. la culture de cellules dans au moins un bioréacteur à densité de cellules élevée, reliant de ce fait à fluide ledit bioréacteur à une alimentation en milieu de culture et à un gaz ou mélange gazeux ; b. liaison à fluide dudit bioréacteur avec une unité aval ; et c. croissance des cellules à une densité d'au moins 50 millions de cellules par ml ; dans lequel le volume total de bioréacteur est d'au moins 10 litres et d'au plus 900 L.
- 2. Procédé selon la revendication 1, dans lequel le volume total de bioréacteur est au plus de 800 L, de préférence au plus 700 L, plus de préférence au plus 500 L.
- 3. Procédé selon l'une quelconque des revendications précédentes, dans lequel ledit milieu de culture et le gaz ou mélange gazeux sont fournis audit bioréacteur par une conduite d’alimentation unique.
- 4. Procédé selon l'une quelconque des revendications précédentes, dans lequel le coefficient de transfert d'oxygène (kLa) dans le bioréacteur est d'au moins 20 h1.
- 5. Procédé selon l'une quelconque des revendications précédentes, dans lequel ladite unité aval reçoit du milieu de culture complété en provenance dudit bioréacteur en mode continu, ledit milieu de culture complété comprend du milieu de culture et/ou des cellules cultivées et/ou des produits desdites cellules cultivées comprenant des protéines, des peptides et/ou toutes autres biomolécules de cellule tirées de la lyse de cellule comme des membranes cellulaires.
- 6. Procédé selon l'une quelconque des revendications précédentes, dans lequel ladite unité aval reçoit au plus 1 000 ml/min de milieu de culture complété en provenance dudit bioréacteur.
- 7. Procédé selon n’importe laquelle des revendications précédentes, dans lequel le milieu de culture complété reçu par l'unité aval subit au moins un processus sélectionné à partir du groupe comprenant la filtration, la collecte, la dialyse, la purification de biomolécules et la concentration protéique ou n'importe quelle combinaison de celles-ci.
- 8. Procédé selon l'une quelconque des revendications précédentes, dans lequel ledit bioréacteur est un bioréacteur à perfusion ou un bioréacteur muni de supports fournissant une surface de croissance cellulaire d'au moins 1 000 m2.
- 9. Système pour la production d'anticorps, comprenant une unité de culture de cellules et une unité aval qui sont reliées à fluide l'une à l'autre, ladite unité de culture de cellules comprend au moins un bioréacteur à perfusion, qui permet la croissance de cellules à une densité d'au moins 50 millions de cellules par ml, et un moyen d'alimentation pour alimenter ledit bioréacteur en milieu de cellule et en gaz ou mélange gazeux, caractérisé en ce que le volume total de bioréacteur est d'au moins 10 litres et d'au plus 900 L
- 10. Système selon la revendication 9, dans lequel le volume total de bioréacteur est au plus de 800 L, de préférence au plus 700 L, plus de préférence au plus 500 L.
- 11. Système selon l'une quelconque des revendications 9 et 10, dans lequel le bioréacteur est un bioréacteur à perfusion.
- 12. Système selon l'une quelconque des revendications 9 à 11, dans lequel ledit bioréacteur est muni de supports.
- 13. Système selon la revendication 12, dans lequel lesdits supports fournissent une surface de croissance cellulaire d'au moins 1 000 m2.
- 14. Système selon l'une quelconque des revendications 9 à 13, dans lequel ladite unité aval comprend un moyen enfichable sélectionné à partir du groupe comprenant au moins un moyen de filtration, au moins un moyen de collecte, au moins un moyen de dialyse, au moins un moyen de purification de biomolécules et au moins une unité de concentration protéique ou n'importe quelle combinaison de ceux-ci.
- 15. Système selon l'une quelconque des revendications 9 à 14, dans lequel ledit système est mis en œuvre dans une chambre transportable, appropriée pour une chambre propre transportable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14154418 | 2014-02-10 | ||
EP14154418.9 | 2014-02-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
BE1023557A1 BE1023557A1 (fr) | 2017-05-03 |
BE1023557B1 true BE1023557B1 (fr) | 2017-05-03 |
Family
ID=50070415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2015/5060A BE1023557B1 (fr) | 2014-02-10 | 2015-02-09 | Systeme, appareil et procede pour la production de biomolecules |
Country Status (4)
Country | Link |
---|---|
US (1) | US10494421B2 (fr) |
EP (1) | EP3105311A1 (fr) |
BE (1) | BE1023557B1 (fr) |
WO (1) | WO2015118146A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012048276A2 (fr) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Procédés et systèmes configurables pour la culture et la récolte de cellules dans un système de bioréacteur à fibres creuses |
WO2015073918A1 (fr) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expansion de cellules dans un bioréacteur |
US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
EP3198006B1 (fr) | 2014-09-26 | 2021-03-24 | Terumo BCT, Inc. | Alimentation programmée |
WO2017004592A1 (fr) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Croissance cellulaire à l'aide de stimuli mécaniques |
JP7034949B2 (ja) | 2016-05-25 | 2022-03-14 | テルモ ビーシーティー、インコーポレーテッド | 細胞の増殖 |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
BE1024733B1 (fr) | 2016-11-09 | 2018-06-14 | Univercells Sa | Matrice de croissance cellulaire |
JP7393945B2 (ja) | 2017-03-31 | 2023-12-07 | テルモ ビーシーティー、インコーポレーテッド | 細胞増殖 |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
US20210130760A1 (en) | 2017-12-20 | 2021-05-06 | Univercells Technologies S.A. | Bioreactor and related methods |
US11603527B2 (en) * | 2017-12-27 | 2023-03-14 | Global Life Sciences Solutions Usa Llc | Method and kit for viral vector isolation |
SG11202100317YA (en) * | 2018-07-27 | 2021-02-25 | Univercells Tech S A | System and method for the production of biomolecules |
WO2020163329A1 (fr) | 2019-02-05 | 2020-08-13 | Corning Incorporated | Substrats de culture cellulaire tissés |
US11118151B2 (en) | 2019-11-05 | 2021-09-14 | Corning Incorporated | Fixed bed bioreactor and methods of using the same |
WO2021197249A1 (fr) * | 2020-03-30 | 2021-10-07 | 上海复宏汉霖生物技术股份有限公司 | Système et procédé de purification continue de molécules cibles |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4839284A (en) | 1985-05-16 | 1989-06-13 | New York University | Murine host-vector system capable of amplifying and expressing transfected genes |
IL82093A (en) | 1986-04-09 | 1992-12-01 | Lilly Co Eli | Method of using eukaryotic expression vectors comprising the bk virus enhancer |
WO1991002793A1 (fr) | 1989-08-25 | 1991-03-07 | Her Majesty In Right Of Canada As Represented By The National Research Council Of Canada | Developpement d'une cardiomyopathie chez des mammiferes non humains transgeniques |
KR100372934B1 (ko) | 1990-09-25 | 2003-12-24 | 캔탑 파마슈티칼스 리서취 리미티드 | 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신 |
JPH04228066A (ja) | 1990-10-23 | 1992-08-18 | Rikagaku Kenkyusho | 外来遺伝子発現用培養細胞 |
WO1995013377A1 (fr) | 1993-11-12 | 1995-05-18 | Case Western Reserve University | Vecteur d'expression episomique destine a la therapie genique humaine |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
JP3877769B2 (ja) | 1995-06-02 | 2007-02-07 | 湧永製薬株式会社 | 組み換えレトロウイルス産生細胞 |
ES2301178T3 (es) | 1996-04-05 | 2008-06-16 | Novartis Vaccines & Diagnostic | Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular. |
GB9701492D0 (en) | 1997-01-24 | 1997-03-12 | Univ Edinburgh | Transfection of embryonic stem cells |
EP0856585A1 (fr) | 1997-01-29 | 1998-08-05 | Introgene B.V. | Un système d'expression et de réplication inductible |
AU1536999A (en) | 1997-11-26 | 1999-06-15 | Board Of Regents, The University Of Texas System | Modified sv40 viral vectors |
CA2311395C (fr) | 1997-11-28 | 2006-11-28 | The Crown In The Right Of The Queensland Department Of Health | Systeme d'expression et de diffusion propre au flavivirus |
US8026096B1 (en) | 1998-10-08 | 2011-09-27 | Protein Sciences Corporation | In vivo active erythropoietin produced in insect cells |
AU776562B2 (en) | 1998-12-02 | 2004-09-16 | University Of Maryland At Baltimore | Plasmid maintenance system for antigen delivery |
US6214221B1 (en) * | 1999-02-22 | 2001-04-10 | Henry B. Kopf | Method and apparatus for purification of biological substances |
EP1175931A1 (fr) | 2000-07-25 | 2002-01-30 | Computer Cell Culture Center S.A. | Intégration de la mise en oeuvre d'un bioréacteur à haute densité cellulaire avec traitement ultérieur en ligne ultrarapide |
AU9322201A (en) | 2000-08-29 | 2002-03-13 | American Cyanamid Co | Packaging of positive-strand rna virus replicon particles |
EP1402023A4 (fr) | 2001-05-31 | 2005-06-15 | Univ Rockefeller | Methode de generation de vecteurs viraux defectifs pour la replication exempts de virus assistant |
IL145463A0 (en) | 2001-09-16 | 2002-06-30 | Yissum Res Dev Co | A packaging complementation cell-line for sv40 vectors |
WO2003046189A1 (fr) | 2001-11-26 | 2003-06-05 | The University Of Queensland | Systeme d'administration d'un vaccin a base de flavivirus |
AU2003222068A1 (en) | 2002-03-25 | 2003-10-13 | University Of North Carolina At Chapel Hill | Improved methods for achieving expression from alphavirus vectors |
WO2004009850A1 (fr) | 2002-07-18 | 2004-01-29 | Micrologix Biotech Inc. | Systeme de replication du virus de l'hepatite c et procedes d'utilisation |
AU2003902842A0 (en) | 2003-06-06 | 2003-06-26 | The University Of Queensland | Flavivirus replicon packaging system |
ES2222095B1 (es) | 2003-07-02 | 2005-11-16 | Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia | Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones. |
PT1651666E (pt) | 2003-07-11 | 2009-08-28 | Alphavax Inc | Vacinas de citomegalovírus à base de alfavírus |
AU2004270765B2 (en) | 2003-09-09 | 2010-03-04 | Acyte Biotech Pty Ltd | Rodent expression systems utilising Polyoma Virus and Epstein Barr Virus sequences |
TW200526775A (en) | 2004-02-12 | 2005-08-16 | Cesco Bioengineering Co Ltd | Cell culture device with auxiliary agitation element |
AU2013203461B2 (en) * | 2004-03-05 | 2016-03-17 | Patheon Holdings I B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
US7264923B2 (en) | 2004-05-05 | 2007-09-04 | Washington University | Norovirus infected cell cultures and uses therefor |
CN101018860B (zh) | 2004-07-12 | 2013-02-27 | 美国天甲生物医药有限公司 | 黄病毒疫苗 |
SI1789084T1 (sl) | 2004-09-09 | 2011-03-31 | Novartis Vaccines & Diagnostic | Zmanjševanje potencialnih iatrogenih tveganj, povezanih z influenčnimi cepivi |
IL164850A0 (en) | 2004-10-26 | 2005-12-18 | Yissum Res Dev Co | Gene therapy for kidney diseases |
US7790446B2 (en) | 2005-02-11 | 2010-09-07 | Kosagen Cell Factory Oü | Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products |
US20060292690A1 (en) | 2005-06-22 | 2006-12-28 | Cesco Bioengineering Co., Ltd. | Method of making cell growth surface |
US20070111309A1 (en) | 2005-10-04 | 2007-05-17 | Daelli Marcelo G | Vero cell line adapted to grow in suspension |
US20090280565A1 (en) | 2005-12-22 | 2009-11-12 | Corporation De L'ecole Polytechique Montr'eal | High-rate perfusion bioreactor |
WO2007139747A1 (fr) | 2006-05-22 | 2007-12-06 | Biovest International Inc. | Interface de module matériel de culture faisant partie d'un système de culture cellulaire et procédé pour l'installer |
GB2439543A (en) | 2006-06-27 | 2008-01-02 | Viruvation B V | Polyoma viral vector production cell lines and nucleic acids expressing dsRNA viral sequences |
EP2066346B1 (fr) * | 2006-09-12 | 2019-07-03 | AlphaVax, Inc. | Particules de réplicon d'alphavirus utilisées en tant qu'adjuvants immunologiques |
EP2162665B1 (fr) | 2007-05-23 | 2015-11-11 | Eppendorf, Inc. | Procédé et appareil de fabrication d'un raccordement fluidique à un conteneur |
PL2183368T3 (pl) | 2007-06-21 | 2016-12-30 | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych | |
WO2009023562A2 (fr) * | 2007-08-09 | 2009-02-19 | Wyeth | Utilisation de la perfusion pour améliorer la production d'une culture cellulaire en mode semi-continu dans des bioréacteurs |
US8530233B2 (en) | 2007-10-02 | 2013-09-10 | Genetai Inc | Expression vector with enhanced gene expression capacity and method for using the same |
WO2009079185A2 (fr) | 2007-11-26 | 2009-06-25 | Novartis Vaccines And Diagnostics, Inc. | Procédés de génération de particules d'alphavirus |
KR20100113112A (ko) | 2008-01-15 | 2010-10-20 | 아보트 러보러터리즈 | 개선된 포유동물 발현 벡터 및 이의 용도 |
US20110201119A1 (en) | 2008-08-15 | 2011-08-18 | Weiguo Zhai | Alphavirus packaging cell lines |
WO2010048417A2 (fr) | 2008-10-22 | 2010-04-29 | Biovest International, Inc. | Bioréacteur à perfusion, systèmes de culture cellulaire et procédés de production de cellules et de produits dérivés de cellule |
CN101864361B (zh) | 2009-04-16 | 2013-02-06 | 赛宇细胞科技股份有限公司 | 可放大的细胞培养装置 |
EP2243836A1 (fr) | 2009-04-22 | 2010-10-27 | Amarna Therapeutics B.V. | Procédé pour la production de particules de vecteur de polymavirus recombinant |
EP2478107B1 (fr) | 2009-09-15 | 2018-08-29 | Medimmune Limited | Cellules pour une expression transitoire et leurs utilisations |
EP2314707A1 (fr) | 2009-10-26 | 2011-04-27 | Amarna Therapeutics B.V. | Procédé pour l'expression d'une protéine recombinante dans une cellule de mammifère |
US20110182901A1 (en) | 2010-01-26 | 2011-07-28 | Institut Curie | Full length large t tumor antigen of merkel cell polyomavirus as a therapeutic target in merkel cell carcinoma |
GB201002082D0 (en) | 2010-02-09 | 2010-03-24 | Univ Leiden Medical Ct | Biological material |
US20130203151A1 (en) | 2010-04-26 | 2013-08-08 | Scott Balsitis | Production of alphavirus replicon particles in packaging cells |
WO2011142667A1 (fr) * | 2010-05-12 | 2011-11-17 | Xpand Biotechnology B.V. | Poche de culture cellulaire |
WO2012171030A2 (fr) | 2011-06-10 | 2012-12-13 | Biovest International, Inc. | Procédé et appareil de production et de purification d'anticorps |
JP5863338B2 (ja) | 2011-08-25 | 2016-02-16 | 株式会社東芝 | プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット |
US20130071872A1 (en) | 2011-09-15 | 2013-03-21 | Lewis Ho | Device and method for single-used matrix sampling |
GB201211256D0 (en) | 2012-06-25 | 2012-08-08 | Glaxosmithkline Biolog Sa | Fermentation process |
JP5939650B2 (ja) | 2013-01-07 | 2016-06-22 | 賽宇細胞科技股▲ふん▼有限公司 | 充填ベッド培養装置のための大規模な細胞採取方法 |
MX2017010217A (es) * | 2015-02-09 | 2017-11-10 | Univercells Nv | Sistema, aparato y metodo para la produccion de celulas y/o productos de celulas. |
-
2015
- 2015-02-09 EP EP15705236.6A patent/EP3105311A1/fr active Pending
- 2015-02-09 US US15/117,691 patent/US10494421B2/en active Active
- 2015-02-09 BE BE2015/5060A patent/BE1023557B1/fr active
- 2015-02-09 WO PCT/EP2015/052617 patent/WO2015118146A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20160355572A1 (en) | 2016-12-08 |
US10494421B2 (en) | 2019-12-03 |
BE1023557A1 (fr) | 2017-05-03 |
EP3105311A1 (fr) | 2016-12-21 |
WO2015118146A1 (fr) | 2015-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE1023557B1 (fr) | Systeme, appareil et procede pour la production de biomolecules | |
BE1022441B1 (fr) | Systeme, appareil et procede pour production de biomolecules | |
BE1022439B1 (fr) | Systeme appareil et procede pour production de biomolecules | |
US20220017850A1 (en) | System, apparatus and method for the production of cells and/or cell products | |
Zydney | New developments in membranes for bioprocessing–A review | |
Kalyanpur | Downstream processing in the biotechnology industry | |
JP6676073B2 (ja) | クロマトグラフィーカラムからプロダクトを連続的に溶出する方法 | |
JP6605504B2 (ja) | タンパク質溶液からバッファーまたは媒体を連続的に交換するための限外ろ過ユニット | |
ES2864721T3 (es) | Disposición y proceso continuo de un biorreactor para la producción y captura de un biopolímero | |
CN108883368B (zh) | 用于处理生物分子的溶液的方法 | |
JP6951341B2 (ja) | 生体分子溶液を濃縮するためのタンジェンシャルフロー濾過プロセス | |
TW201522363A (zh) | 用於純化抗體之連續多步驟方法 | |
KR20140059753A (ko) | 생물학적 산물을 위한 연속 처리 방법 | |
BE1024230B1 (fr) | Production contenue de cellules et/ou de produits cellulaires | |
JP2021513985A (ja) | 標的物質を含む液体を処理するための装置 | |
BE1022269B1 (fr) | Système, appareil et procédé pour la production de cellules et/ou de produits cellulaires | |
CN114555774A (zh) | 用于纯化目标物质的方法 | |
EP4347778A1 (fr) | Plate-forme de production de bioprocédé continu intégré |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RC | Pledge established (pawning) |
Free format text: DETAILS PLEDGE: RIGHT OF PLEDGE, ETABLI Name of requester: EUROPEAN INVESTMENT BANK Effective date: 20191017 |
|
PD | Change of ownership |
Owner name: UNIVERCELLS TECHNONOLOGIES S.A.; BE Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION Effective date: 20200407 |
|
RF | Seizure terminated |
Free format text: DETAILS PLEDGE: RIGHT OF PLEDGE, REMOVED Name of requester: EUROPEAN INVESTMENT BANK Effective date: 20200305 |